Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER studyPierFranco Conte, Valentina Guarneri, Antonio Frassoldati et al.|Annals of Oncology|2018Cited by 157
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 studyMarina Elena Cazzaniga, Massimiliano Mazza, G. Pinotti et al.|The Breast|2019Cited by 58
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 studyMarina Elena Cazzaniga, I. Vallini, Emilia Montagna et al.|Breast Cancer Research and Treatment|2021Cited by 17
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patientsB. Trevisan, Francesca Fulvia Pepe, I. Vallini et al.|Scientific Reports|2023Cited by 5
Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER studyLuca Arecco, Lucia Del Mastro, Maria Maddalena Latocca et al.|The Breast|2024Cited by 3